Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Gains from Sales and Divestitures (2016 - 2026)

Anika Therapeutics has reported Gains from Sales and Divestitures over the past 15 years, most recently at $310370.0 for Q1 2026.

  • Quarterly Gains from Sales and Divestitures rose 24.06% to $310370.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $310370.0 through Mar 2026, up 24.06% year-over-year, with the annual reading at $317850.0 for FY2025, 2.06% up from the prior year.
  • Gains from Sales and Divestitures was $310370.0 for Q1 2026 at Anika Therapeutics, down from $317850.0 in the prior quarter.
  • Over five years, Gains from Sales and Divestitures peaked at $317850.0 in Q4 2025 and troughed at $19125.0 in Q2 2022.
  • The 5-year median for Gains from Sales and Divestitures is $250172.0 (2025), against an average of $212820.2.
  • Year-over-year, Gains from Sales and Divestitures plummeted 79.14% in 2022 and then soared 1254.95% in 2023.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $19125.0 in 2022, then soared by 1254.95% to $259134.0 in 2023, then grew by 20.19% to $311441.0 in 2024, then grew by 2.06% to $317850.0 in 2025, then dropped by 2.35% to $310370.0 in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Gains from Sales and Divestitures are $310370.0 (Q1 2026), $317850.0 (Q4 2025), and $316105.0 (Q2 2025).